RG7388 + Pegasys
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Polycythemia Vera
Conditions
Polycythemia Vera, Essential Thrombocythemia
Trial Timeline
Apr 1, 2015 → Dec 19, 2018
NCT ID
NCT02407080About RG7388 + Pegasys
RG7388 + Pegasys is a phase 1 stage product being developed by Roche for Polycythemia Vera. The current trial status is completed. This product is registered under clinical trial identifier NCT02407080. Target conditions include Polycythemia Vera, Essential Thrombocythemia.
What happened to similar drugs?
2 of 17 similar drugs in Polycythemia Vera were approved
Approved (2) Terminated (1) Active (15)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02407080 | Phase 1 | Completed |
Competing Products
20 competing products in Polycythemia Vera
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Sapablursen + Placebo | Ono Pharmaceutical | Phase 3 | 47 |
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 36 |
| Bomedemstat | Merck | Phase 2 | 35 |
| Ruxolitinib + Hydroxycarbamide + Interferon-Alpha | Novartis | Phase 3 | 47 |
| ruxolitinib tablets | Novartis | Phase 3 | 40 |
| Ruxolitinib | Novartis | Pre-clinical | 26 |
| Ruxolitinib | Novartis | Phase 3 | 40 |
| Ruxolitinib + BAT | Novartis | Phase 2 | 39 |
| Hydroxyurea | Novartis | Approved | 35 |
| Best Available Therapy + Ruxolitinib | Novartis | Phase 3 | 40 |
| Smac Mimetic LCL161 | Novartis | Phase 2 | 35 |
| PEGASYS + Aspirin | Roche | Phase 2 | 35 |
| Idasanutlin | Roche | Phase 2 | 27 |
| PEGASYS + Hydroxyurea + Aspirin | Roche | Phase 3 | 40 |
| Ropeginterferon alfa-2b | PharmaEssentia | Phase 2 | 39 |
| Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen | PharmaEssentia | Phase 3 | 40 |
| Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT) | PharmaEssentia | Phase 3 | 40 |
| Ropeginterferon alfa-2b | PharmaEssentia | Approved | 50 |
| P1101 + Low-dose aspirin | PharmaEssentia | Phase 2 | 35 |
| P1101 (Ropeginterferon alfa-2b) | PharmaEssentia | Phase 3 | 47 |